Johnson Controls expands Denmark heat pump facility
Get Alerts JCI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
EPS Growth %: +22.9%
Join SI Premium – FREE
Johnson Controls (NYSE: JCI) expanded its heat pump and chiller facility in Holme, Denmark, adding production and testing capabilities to meet European demand for high-capacity heat pumps.
The expansion includes 2,300 square meters of new production space and an 1,800 square meter customer experience and test center compliant with European Heat Pump Association testing standard EN 14511. The project is expected to create more than 100 local jobs and includes modernization of existing buildings at the site.
The facility operates on 100% green energy and manufactures customized Sabroe-branded heat pumps and chillers using zero and low global warming potential refrigerants designed to align with EU regulations taking effect from 2027 and 2030.
"With generations of manufacturing expertise in Europe and a market-leading position in commercial and large-scale heat pumps, this expansion in Holme reinforces our long-term commitment to building critical technologies here, for Europe," said Richard Lek, president EMEA at Johnson Controls.
EU Commissioner for Energy & Housing Dan Jørgensen and Mayor Anders Winnerskjold from the City of Aarhus attended the facility opening ceremony.
Johnson Controls reports its heat pump solutions helped customers reduce heating energy costs by up to 32% and cut emissions by up to 55% in 2025. The company has delivered large-scale heat pumps to customers including Vattenfall Berlin and New Aalborg University Hospital in Denmark.
The Holme facility complements Johnson Controls' European manufacturing sites in Nantes, France; Milan, Italy; Cork, Ireland and Budapest, Hungary.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
- Leerink highlights drug demand rebound after Memorial Day
- AstraZeneca receives FDA approval for Truqap prostate cancer treatment
Create E-mail Alert Related Categories
Corporate News, Hot Corp. NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share